Reported Saturday, Alumis' Phase 3 ONWARD Trials Show Envudeucitinib Delivers Robust Skin Clearance And Early Itch Relief In Over 1,700 Plaque Psoriasis Patients, NDA Planned H2 2026

Alumis' Phase 3 ONWARD trials for Envudeucitinib showed significant efficacy in treating plaque psoriasis, with PASI 90 responses of 68.0% and PASI 100 responses of 41.0% by Week 24. The treatment also provided early itch relief and quality-of-life improvements, with notable results emerging as early as Week 4. The drug demonstrated a favorable safety profile, and the findings were presented at the 2026 American Academy of Dermatology Annual Meeting. Alumis plans to file a New Drug Application (NDA) in the second half of 2026.